Yoichi Imai

Tochigi, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 64 publications

Long-term remission with venetoclax plus azacitidine in acute myeloid leukemia with negative conversion of FLT3 companion diagnostic testing at relapse

Long-term remission with venetoclax plus azacitidine in acute myeloid leukemia with negative conversion of FLT3 companion diagnostic testing at relapse

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: August 03, 2026

Preface

Preface

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: July 06, 2025

Outcomes of patients aged 70 years or younger with aggressive ATL at core hospitals for ATL treatment in Tokyo.

Outcomes of patients aged 70 years or younger with aggressive ATL at core hospitals for ATL treatment in Tokyo.

Journal: International journal of hematology

Published: March 15, 2025

HDAC inhibitors repress Tek and Angpt1 expression and proliferation in RUNX1-MECOM-type leukemia cells.

HDAC inhibitors repress Tek and Angpt1 expression and proliferation in RUNX1-MECOM-type leukemia cells.

Journal: Leukemia research

Published: December 22, 2024

A CML Patient Carrying BCR::ABL1 Splicing Variants Did Not Experience Blast Crisis for 15 Years without Responding to Various TKIs.

A CML Patient Carrying BCR::ABL1 Splicing Variants Did Not Experience Blast Crisis for 15 Years without Responding to Various TKIs.

Journal: Internal medicine (Tokyo, Japan)

Published: August 28, 2024

A whole gamma imaging prototype for higher quantitative imaging of89Zr-labeled antibodies in a tumor mouse model.

A whole gamma imaging prototype for higher quantitative imaging of89Zr-labeled antibodies in a tumor mouse model.

Journal: Physics in medicine and biology

Published: June 14, 2024

Novel treatment strategies for hematological malignancies in the immunotherapy era.

Novel treatment strategies for hematological malignancies in the immunotherapy era.

Journal: International journal of hematology

Published: May 02, 2024

Evolution of natural killer cell-targeted therapy for acute myeloid leukemia.

Evolution of natural killer cell-targeted therapy for acute myeloid leukemia.

Journal: International journal of hematology

Published: March 15, 2024

SETDB1 suppresses NK cell-mediated immunosurveillance in acute myeloid leukemia with granulo-monocytic differentiation.

SETDB1 suppresses NK cell-mediated immunosurveillance in acute myeloid leukemia with granulo-monocytic differentiation.

Journal: Cell reports

Published: November 17, 2023

Current and Future PET Imaging for Multiple Myeloma.

Current and Future PET Imaging for Multiple Myeloma.

Journal: Life (Basel, Switzerland)

Published: June 07, 2023

Immune checkpoint molecule DNAM-1/CD112 axis is a novel target for natural killer-cell therapy in acute myeloid leukemia.

Immune checkpoint molecule DNAM-1/CD112 axis is a novel target for natural killer-cell therapy in acute myeloid leukemia.

Journal: Haematologica

Published: February 08, 2023

Progression to B acute lymphoblastic leukemia in 8p11 myeloproliferative syndrome with t(6;8)(q27;p12).

Progression to B acute lymphoblastic leukemia in 8p11 myeloproliferative syndrome with t(6;8)(q27;p12).

Journal: International journal of hematology

Published: December 01, 2022

Showing 1-12 of 64

Last Updated: 09/26/2026